MiniMed Group (NASDAQ:MMED) Research Coverage Started at Barclays

Barclays assumed coverage on shares of MiniMed Group (NASDAQ:MMED) in a research report sent to investors on Wednesday, Marketbeat reports. The brokerage issued an equal weight rating and a $22.00 price target on the stock.

Several other research analysts have also recently issued reports on the stock. BTIG Research raised their target price on shares of MiniMed Group from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, September 1st. Morgan Stanley increased their price target on shares of MiniMed Group from $19.00 to $21.00 and gave the company an “overweight” rating in a research report on Thursday, September 3rd. Truist Financial initiated coverage on shares of MiniMed Group in a report on Thursday, September 24th. They issued a “buy” rating and a $29.00 price target on the stock. Weiss Ratings upgraded shares of MiniMed Group from a “sell (d-)” rating to a “sell (d)” rating in a research report on Wednesday, September 9th. Finally, Citigroup upped their price objective on shares of MiniMed Group from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

MiniMed Group Price Performance

MMED opened at $19.71 on Wednesday. The stock’s 50 day simple moving average is $20.63 and its 200 day simple moving average is $16.42. The firm has a market cap of $5.55 billion and a price-to-earnings ratio of -28.99. MiniMed Group has a 1 year low of $10.65 and a 1 year high of $24.43.

Institutional Investors Weigh In On MiniMed Group

A number of institutional investors have recently modified their holdings of the stock. State Street Corp bought a new position in shares of MiniMed Group during the second quarter valued at $6,029,000. The Manufacturers Life Insurance Company bought a new position in MiniMed Group in the 2nd quarter worth about $185,000. WINTON GROUP Ltd bought a new position in MiniMed Group in the 2nd quarter worth about $273,000. Engineers Gate Manager LP purchased a new stake in MiniMed Group during the 2nd quarter valued at about $513,000. Finally, Squarepoint Ops LLC bought a new stake in MiniMed Group during the 2nd quarter valued at about $403,000.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.